<DOC>
	<DOCNO>NCT00062595</DOCNO>
	<brief_summary>This one year study K vitamers phylloquinone ( K1 ) menatetranone ( MK4 ) study supplementation effect bone turnover bone density . Women least 5 year postmenopause normal bone density use estrogen therapy follow medication may eligible : alendronate ( Fosamax ) , risedronate ( Actonel ) , pamidronate ( Aredia ) , etidronate ( Didronel ) , zoledronate ( Zometa ) , teriparatide ( Forteo ) , raloxifene ( Evista ) , tamoxifene , warfarin ( Coumadin ) , anti-seizure medication , prednisone , oral steroid . Eligible subject take calcium vitamin D ( Citracal ) twice day first two month through-out study . After first two month , subject randomize K1 , MK4 placebo group . Return visit occur 1 , 3 , 6 12 month . Fasting blood urine collect visit bone density perform 3 study visit .</brief_summary>
	<brief_title>Vitamin K Bone Turnover Postmenopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin K</mesh_term>
	<mesh_term>Vitamin K 1</mesh_term>
	<criteria>Female , 5 year postmenopause . Ambulatory . Community dwell . Able ingest calcium vitamin D supplement . Willing restrict vitamin K intake . Stable thyroid dose appropriate . No history hyperthyroidism , hyperparathyroidism metabolic bone disease . Absence hardware hip spine . History malignancy within last five year . Not currently use coumadin warfarin . Vitamin D supplement must less 800 IU daily . Have use estrogen bonealtering medication ( see list study description ) within last year . No history liver disease malabsorption . No known allergy vitamin K. Have participate investigational drug trial within last month .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Menopause</keyword>
	<keyword>Vitamin K</keyword>
	<keyword>Bone turnover</keyword>
	<keyword>Bone Density</keyword>
</DOC>